This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Scopus Google Scholar Articles by Zandman-Goddard, G Articles by Shoenfeld, Y PubMed PubMed Citation Articles by Zandman-Goddard, G Articles by Shoenfeld, Y Social Bookmarking                         What's this?

Intravenous immunoglobulins in systemic lupus erythematosus: from the bench to the bedside

Department of Medicine C, Wolfson Medical Center, Israel; The Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel

M Blank

The Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel; Department of Medicine 'B' and The Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Israel

Y Shoenfeld

The Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel; Department of Medicine 'B' and The Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Israel; Incumbent of the Laura Schwartz-Kipp Chair for Research of Autoimmune Diseases, Tel-Aviv University, Tel Aviv, Israelshoenfel{at}post.tau.ac.il

This article is an update on the clinical and research data available on systemic lupus erythematosus (SLE) and intravenous immunoglobulin (IVIg) therapy that includes some studies performed under the umbrella of the European Working Party on SLE. Various mechanisms of IVIg may play a role, some synergistically, in the modulation of SLE. Recently it has been suggested that IVIg also suppresses the expansion of autoreactive B lymphocytes through signalling of the FcgRIIB, idiotype-mediated inhibition of B cell receptors and neutralisation of cytokines such as the B cell survival factors (B cell activation factor (BAFF and APRIL). In case reports and in open trials, high-dose IVIg (2 g/kg over a 5-day period) has consistently been shown to be a beneficial and safe adjunct therapeutic agent for over 20 manifestations in patients with SLE. It can be given as a first choice of therapy in some cases, for example, in neurological involvement and in those patients who refuse certain immunosuppressive agents such as cyclophosphamide, or in patients who have concomitant infections. Furthermore, IVIg may have a steroid-sparing effect although this characteristic needs further investigation. Specific IVIg (an anti-idiotype to anti-DNA, phosphorylcholine and antiphospholipids) has been shown to be effective in experimental murine models. Hence, extractable IVIg that is directed to the specific pathogenic immunoglobulins will enable the more specific therapy for patients with lupus.

Key Words: intravenous immunoglobulins • IVIg • systemic lupus erythematosus

Lupus, Vol. 18, No. 10, 884-888 (2009)
DOI: 10.1177/0961203309106921


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?